---
title: A Randomized, Comparative Study of Hexvix Fluorescence Cystoscopy and Standard Cystoscopy in Patients With Non-invasive Bladder Cancer
nct_id: NCT00412971
overall_status: COMPLETED
phase: PHASE3
sponsor: Photocure
study_type: INTERVENTIONAL
primary_condition: Bladder Cancer
countries: Denmark
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00412971.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00412971"
ct_last_update_post_date: 2013-10-11
last_seen_at: "2026-05-12T06:34:54.085Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# A Randomized, Comparative Study of Hexvix Fluorescence Cystoscopy and Standard Cystoscopy in Patients With Non-invasive Bladder Cancer

**Official Title:** A Randomized, Comparative Phase III, 2-center Study of Hexvix Fluorescence Cystoscopy and Standard Cystoscopy in Patients With Non-invasive Bladder Cancer

**NCT ID:** [NCT00412971](https://clinicaltrials.gov/study/NCT00412971)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE3
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 233
- **Lead Sponsor:** Photocure
- **Conditions:** Bladder Cancer
- **Start Date:** 2005-04
- **Completion Date:** 2008-10
- **CT.gov Last Update:** 2013-10-11

## Brief Summary

The main objective of the study is to compare the 1-year recurrence rate of Hexvix assisted Transuretheral Resection of the Bladder (TURB) to standard white light TURB in patients with suspicion of non-invasive bladder cancer.

The hypothesis is to test whether the 1-year recurrence rate is different with Hexvix assisted TURB compared to standard white light TURB.

## Detailed Description

The main objective of the study is to compare the 1-year recurrence rate of Hexvix assisted Transuretheral Resection of the Bladder (TURB) to standard white light TURB in patients with suspicion of non-invasive bladder cancer.

Patients will be followed 4, 8 and 12 months after the initial TURB. This follow-up regimen is according to standard clinical practice in Denmark.

Recurrence of non-invasive bladder cancer is frequent, and this study is designed to investigate whether Hexvix assisted TURB can reduce the early recurrence compared to standard TURB

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Patients with suspicion of non-invasive bladder cancer indicated for a transuretheral resection of the bladder
* Above 18 years
* Written informed consent obtained

Exclusion Criteria:

* Gross hematuria. (Note: Gross hematuria is defined as a heavy bladder bleed resulting in marked amounts of blood in the urine, which may interfere with fluorescence cystoscopy. Where the bleed is light, the patient should not be excluded if in the investigator's opinion, rinsing during cystoscopy will alleviate the possible interference with fluorescence cystoscopy).
* Patient with porphyria.
* Known allergy to hexyl aminolevulinate hydrochloride or a similar compound.
* Participation in other clinical studies with investigational drugs either concurrently or within the last 30 days.
* Pregnant or breast-feeding (all women of child-bearing potential must document a negative serum or urine pregnancy test at screening and use the contraceptive pill or intrauterine device (IUD) during the treatments and for at least one month thereafter).
* Conditions associated with a risk of poor protocol compliance.
```

## Arms

- **Hexvix cystoscopy group** (ACTIVE_COMPARATOR)
- **White light** (OTHER) — Standard White light cystoscopy

## Interventions

- **Hexvix** (DRUG) — Single installation, TURB
- **Standard white light cystoscopy** (OTHER)

## Primary Outcomes

- **Proportion of Patients With Histologically Confirmed Recurrence Within One 1 Year.** _(time frame: 1 year)_ — To compare tumour recurrence rates after standard (white light) and fluorescence guided transurethral resection of the bladder (TURB) in patients with macroscopic non-muscle invasive bladder tumour.

## Secondary Outcomes

- **Proportion of Patients in the Hexvix Cystoscopy Group Who Had at Least One Additional Lesion Found by Hexvix Cystoscopy That Was Not Found by White Light Cystoscopy.** _(time frame: At day 0)_
- **False Positive Detection Rate Patient Level** _(time frame: 12 months)_

## Locations (2)

- Frederiksberg Hospital, Frederiksberg, Denmark
- Odense University Hospital, Odense, Denmark

## Recent Field Changes (last 30 days)

- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.frederiksberg hospital|frederiksberg||denmark` — added _(2026-05-12)_
- `locations.odense university hospital|odense||denmark` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00412971.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00412971*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*